Ocular Therapeutix

Pharma

FDA clears Ocular's Dextenza for eye itching from allergies

Dextenza could reach $250 million in peak sales in eye itching associated with allergic conjunctivitis, Jefferies analyst predicts.
Angus Liu Oct 12, 2021 10:20am

Regeneron scraps sustained-release Eylea alliance with Ocular

Aug 10, 2021 8:45am

Ocular Therapeutix crosses the finish line with eye treatment

Dec 4, 2018 11:15am

Ocular Therapeutix gets second CRL for eye drug

Jul 12, 2017 11:08am

Eye doc calls for more sustained drug delivery systems for ocular surfaces

Sep 13, 2016 12:38am

Valeant, Ocular Therapeutix get CRLs tied to manufacturing

Jul 25, 2016 11:37am